Agonistic nanobodies and antibodies to human VISTA

The V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint regulator that suppresses immune responses and is readily expressed on human and murine myeloid cells and T cells. This immunosuppressive pathway can be activated using VISTA agonists. Here, we report the development of...

Full description

Bibliographic Details
Main Authors: Yu-Heng Vivian Ma, Amanda Sparkes, Ema Romão, Shrayasee Saha, Jean Gariépy
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Series:mAbs
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2021.2003281
_version_ 1798040840981970944
author Yu-Heng Vivian Ma
Amanda Sparkes
Ema Romão
Shrayasee Saha
Jean Gariépy
author_facet Yu-Heng Vivian Ma
Amanda Sparkes
Ema Romão
Shrayasee Saha
Jean Gariépy
author_sort Yu-Heng Vivian Ma
collection DOAJ
description The V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint regulator that suppresses immune responses and is readily expressed on human and murine myeloid cells and T cells. This immunosuppressive pathway can be activated using VISTA agonists. Here, we report the development of murine anti-human VISTA (anti-hVISTA) monoclonal antibodies (mAbs), anti-hVISTA nanobodies (Nbs), and cross-reactive rat anti-murine/human VISTA (anti-hmVISTA) mAbs. All mAbs and Nbs generated bound to VISTA (human and/or murine) with dissociation constants in the sub-nanomolar or low nanomolar range. Competition analysis revealed that the selected Nbs bound the same or a nearby epitope(s) as the human VISTA-specific mAbs. However, the cross-reactive mAbs only partially competed with Nbs for binding to hVISTA. All mAbs and one Nb (hVISTANb7) were able to strongly detect VISTA expression on primary human monocytes. Importantly, the murine anti-hVISTA mAbs 7E12 and 7G5 displayed strong agonistic activity in human peripheral blood mononuclear cell cultures, while Nb7 and rat anti-hmVISTA mAbs 3C3, 7C6, 7C7, and 7G1 also behaved as hVISTA agonists, albeit to a lesser extent. Cross-reactive mAbs 7C7 and 7G1 further displayed agonistic potential in murine splenocyte assays. Importantly, mAb 7G1 significantly reduced inflammation associated with the murine model of imiquimod-induced psoriasis. These agonistic VISTA mAbs may represent therapeutic leads to treat inflammatory disorders.
first_indexed 2024-04-11T22:13:13Z
format Article
id doaj.art-f59647e7b99f4f21a7e6a706007da58e
institution Directory Open Access Journal
issn 1942-0862
1942-0870
language English
last_indexed 2024-04-11T22:13:13Z
publishDate 2021-01-01
publisher Taylor & Francis Group
record_format Article
series mAbs
spelling doaj.art-f59647e7b99f4f21a7e6a706007da58e2022-12-22T04:00:31ZengTaylor & Francis GroupmAbs1942-08621942-08702021-01-0113110.1080/19420862.2021.2003281Agonistic nanobodies and antibodies to human VISTAYu-Heng Vivian Ma0Amanda Sparkes1Ema Romão2Shrayasee Saha3Jean Gariépy4Physical Sciences, Sunnybrook Research Institute, Toronto, CanadaPhysical Sciences, Sunnybrook Research Institute, Toronto, CanadaCellular and Molecular Immunology Lab, Vrije Universiteit Brussel, Ixelles, BelgiumDepartment of Pharmaceutical Sciences, University of Toronto, Toronto, CanadaPhysical Sciences, Sunnybrook Research Institute, Toronto, CanadaThe V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint regulator that suppresses immune responses and is readily expressed on human and murine myeloid cells and T cells. This immunosuppressive pathway can be activated using VISTA agonists. Here, we report the development of murine anti-human VISTA (anti-hVISTA) monoclonal antibodies (mAbs), anti-hVISTA nanobodies (Nbs), and cross-reactive rat anti-murine/human VISTA (anti-hmVISTA) mAbs. All mAbs and Nbs generated bound to VISTA (human and/or murine) with dissociation constants in the sub-nanomolar or low nanomolar range. Competition analysis revealed that the selected Nbs bound the same or a nearby epitope(s) as the human VISTA-specific mAbs. However, the cross-reactive mAbs only partially competed with Nbs for binding to hVISTA. All mAbs and one Nb (hVISTANb7) were able to strongly detect VISTA expression on primary human monocytes. Importantly, the murine anti-hVISTA mAbs 7E12 and 7G5 displayed strong agonistic activity in human peripheral blood mononuclear cell cultures, while Nb7 and rat anti-hmVISTA mAbs 3C3, 7C6, 7C7, and 7G1 also behaved as hVISTA agonists, albeit to a lesser extent. Cross-reactive mAbs 7C7 and 7G1 further displayed agonistic potential in murine splenocyte assays. Importantly, mAb 7G1 significantly reduced inflammation associated with the murine model of imiquimod-induced psoriasis. These agonistic VISTA mAbs may represent therapeutic leads to treat inflammatory disorders.https://www.tandfonline.com/doi/10.1080/19420862.2021.2003281VISTAmonoclonal antibodiesnanobodiesagonisticanti-inflammatorypsoriasis
spellingShingle Yu-Heng Vivian Ma
Amanda Sparkes
Ema Romão
Shrayasee Saha
Jean Gariépy
Agonistic nanobodies and antibodies to human VISTA
mAbs
VISTA
monoclonal antibodies
nanobodies
agonistic
anti-inflammatory
psoriasis
title Agonistic nanobodies and antibodies to human VISTA
title_full Agonistic nanobodies and antibodies to human VISTA
title_fullStr Agonistic nanobodies and antibodies to human VISTA
title_full_unstemmed Agonistic nanobodies and antibodies to human VISTA
title_short Agonistic nanobodies and antibodies to human VISTA
title_sort agonistic nanobodies and antibodies to human vista
topic VISTA
monoclonal antibodies
nanobodies
agonistic
anti-inflammatory
psoriasis
url https://www.tandfonline.com/doi/10.1080/19420862.2021.2003281
work_keys_str_mv AT yuhengvivianma agonisticnanobodiesandantibodiestohumanvista
AT amandasparkes agonisticnanobodiesandantibodiestohumanvista
AT emaromao agonisticnanobodiesandantibodiestohumanvista
AT shrayaseesaha agonisticnanobodiesandantibodiestohumanvista
AT jeangariepy agonisticnanobodiesandantibodiestohumanvista